Current Practices for Screening and Management of Financial Distress at NCCN Member Institutions

Authors:
Nandita Khera Mayo Clinic Alix School of Medicine, Phoenix, Arizona;

Search for other papers by Nandita Khera in
Current site
Google Scholar
PubMed
Close
 MD, MPH
,
Jessica Sugalski National Comprehensive Cancer Network, Plymouth Meeting, Pennsylvania;

Search for other papers by Jessica Sugalski in
Current site
Google Scholar
PubMed
Close
 MPPA
,
Diana Krause National Comprehensive Cancer Network, Plymouth Meeting, Pennsylvania;

Search for other papers by Diana Krause in
Current site
Google Scholar
PubMed
Close
 MHA
,
Richard Butterfield III Mayo Clinic Alix School of Medicine, Phoenix, Arizona;

Search for other papers by Richard Butterfield III in
Current site
Google Scholar
PubMed
Close
 MS
,
Nan Zhang Mayo Clinic Alix School of Medicine, Phoenix, Arizona;

Search for other papers by Nan Zhang in
Current site
Google Scholar
PubMed
Close
 MS
,
F. Marc Stewart Fred Hutchinson Cancer Research Center, University of Washington Children’s Hospital, Seattle, Washington;

Search for other papers by F. Marc Stewart in
Current site
Google Scholar
PubMed
Close
 MD
,
Robert W. Carlson National Comprehensive Cancer Network, Plymouth Meeting, Pennsylvania;

Search for other papers by Robert W. Carlson in
Current site
Google Scholar
PubMed
Close
 MD
,
Joan M. Griffin Mayo Clinic, Rochester, Minnesota; and

Search for other papers by Joan M. Griffin in
Current site
Google Scholar
PubMed
Close
 PhD
,
S. Yousuf Zafar Duke University Medical Center, Durham, North Carolina.

Search for other papers by S. Yousuf Zafar in
Current site
Google Scholar
PubMed
Close
 MD
, and
Stephanie J. Lee Fred Hutchinson Cancer Research Center, University of Washington Children’s Hospital, Seattle, Washington;

Search for other papers by Stephanie J. Lee in
Current site
Google Scholar
PubMed
Close
 MD
Restricted access

Background: Financial distress from medical treatment is an increasing concern. Healthcare organizations may have different levels of organizational commitment, existing programs, and expected outcomes of screening and management of patient financial distress. Patients and Methods: In November 2018, representatives from 17 (63%) of the 27 existing NCCN Member Institutions completed an online survey. The survey focused on screening and management practices for patient financial distress, perceived barriers in implementation, and leadership attitudes about such practices. Due to the lack of a validated questionnaire in this area, survey questions were generated after a comprehensive literature search and discussions among the study team, including NCCN Best Practices Committee representatives. Results: Responses showed that 76% of centers routinely screened for financial distress, mostly with social worker assessment (94%), and that 56% screened patients multiple times. All centers offered programs to help with drug costs, meal or gas vouchers, and payment plans. Charity care was provided by 100% of the large centers (≥10,000 unique annual patients) but none of the small centers that responded (<10,000 unique annual patients; P=.008). Metrics to evaluate the impact of financial advocacy services included number of patients assisted, bad debt/charity write-offs, or patient satisfaction surveys. The effectiveness of institutional practices for screening and management of financial distress was reported as poor/very poor by 6% of respondents. Inadequate staffing and resources, limited budget, and lack of reimbursement were potential barriers in the provision of these services. A total of 94% agreed with the need for better integration of financial advocacy into oncology practice. Conclusions: Three-fourths of NCCN Member Institutions reported screening and management programs for financial distress, although the actual practices and range of services vary. Information from this study can help centers benchmark their performance relative to similar programs and identify best practices in this area.

Submitted August 13, 2019; accepted for publication January 15, 2020.

Author contributions: Study and survey design: Khera, Sugalski, Griffin, Zafar, Lee. Literature search and drafting of manuscript: Khera. Survey administration and results compilation: Sugalski, Krause. Statistical analyses: Butterfield, Zhang. Interpretation of findings, critical review, and final approval of manuscript: All authors.

Disclosures: The authors have disclosed that they have not received any financial consideration from any person or organization to support the preparation, analysis, results, or discussion of this article. Ms. Sugalski, Ms. Krause, and Dr. Carlson are employed by NCCN.

Correspondence: Nandita Khera, MD, MPH, Mayo Clinic Alix School of Medicine, 5777 East Mayo Boulevard, Phoenix, AZ 85054. Email: khera.nandita@mayo.edu

Supplementary Materials

    • Supplemental Materials (PDF 871.13 KB)
  • Collapse
  • Expand
  • 1.

    Altice CK, Banegas MP, Tucker-Seeley RD, et al.. Financial hardships experienced by cancer survivors: a systematic review. J Natl Cancer Inst 2016;109:djw205.

  • 2.

    Zafar SY, Peppercorn JM, Schrag D, et al.. The financial toxicity of cancer treatment: a pilot study assessing out-of-pocket expenses and the insured cancer patient’s experience. Oncologist 2013;18:381390.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 3.

    Shankaran V, Jolly S, Blough D, et al.. Risk factors for financial hardship in patients receiving adjuvant chemotherapy for colon cancer: a population-based exploratory analysis. J Clin Oncol 2012;30:16081614.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 4.

    Khera N, Chang YH, Hashmi S, et al.. Financial burden in recipients of allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 2014;20:13751381.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 5.

    Jagsi R, Pottow JAE, Griffith KA, et al.. Long-term financial burden of breast cancer: experiences of a diverse cohort of survivors identified through population-based registries. J Clin Oncol 2014;32:12691276.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 6.

    Kent EE, Forsythe LP, Yabroff KR, et al.. Are survivors who report cancer-related financial problems more likely to forgo or delay medical care? Cancer 2013;119:37103717.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 7.

    Kodama Y, Morozumi R, Matsumura T, et al.. Increased financial burden among patients with chronic myelogenous leukaemia receiving imatinib in Japan: a retrospective survey. BMC Cancer 2012;12:152.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 8.

    Huntington SF, Weiss BM, Vogl DT, et al.. Financial toxicity in insured patients with multiple myeloma: a cross-sectional pilot study. Lancet Haematol 2015;2:e408416.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 9.

    Abel GA, Albelda R, Khera N, et al.. Financial hardship and patient-reported outcomes after hematopoietic cell transplantation. Biol Blood Marrow Transplant 2016;22:15041510.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 10.

    Chino F, Peppercorn J, Taylor DH Jr, et al.. Self-reported financial burden and satisfaction with care among patients with cancer. Oncologist 2014;19:414420.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 11.

    Fenn KM, Evans SB, McCorkle R, et al.. Impact of financial burden of cancer on survivors’ quality of life. J Oncol Pract 2014;10:332338.

  • 12.

    Kelley RK, Venook AP. Nonadherence to imatinib during an economic downturn. N Engl J Med 2010;363:596598.

  • 13.

    Khera N, Holland JC, Griffin JM. Setting the stage for universal financial distress screening in routine cancer care. Cancer 2017;123:40924096.

  • 14.

    de Souza JA, Yap BJ, Wroblewski K, et al.. Measuring financial toxicity as a clinically relevant patient-reported outcome: the validation of the COmprehensive Score for financial Toxicity (COST). Cancer 2017;123:476484.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 15.

    Dusetzina SB, Basch E, Keating NL. For uninsured cancer patients, outpatient charges can be costly, putting treatments out of reach. Health Aff (Millwood) 2015;34:584591.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 16.

    Ramsey SD, Bansal A, Fedorenko CR, et al.. Financial insolvency as a risk factor for early mortality among patients with cancer. J Clin Oncol 2016;34:980986.

  • 17.

    Yabroff KR, Dowling EC, Guy GP Jr, et al.. Financial hardship associated with cancer in the United States: findings from a population-based sample of adult cancer survivors. J Clin Oncol 2016;34:259267.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 18.

    Smith SK, Nicolla J, Zafar SY. Bridging the gap between financial distress and available resources for patients with cancer: a qualitative study. J Oncol Pract 2014;10:e368372.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 19.

    Schrag D, Hanger M. Medical oncologists’ views on communicating with patients about chemotherapy costs: a pilot survey. J Clin Oncol 2007;25:233237.

  • 20.

    Ubel PA, Zhang CJ, Hesson A, et al.. Study of physician and patient communication identifies missed opportunities to help reduce patients’ out-of-pocket spending. Health Aff (Millwood) 2016;35:654661.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 21.

    Altomare I, Irwin B, Zafar SY, et al.. ReCAP: physician experience and attitudes toward addressing the cost of cancer care. J Oncol Pract 2016;12:247248.

  • 22.

    Rosenstock IM, Strecher VJ, Becker MH. Social learning theory and the Health Belief Model. Health Educ Q 1988;15:175183.

  • 23.

    Coluzzi PH, Grant M, Doroshow JH, et al.. Survey of the provision of supportive care services at National Cancer Institute-designated cancer centers. J Clin Oncol 1995;13:756764.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 24.

    Jacobsen PB, Ransom S. Implementation of NCCN Distress Management Guidelines by member institutions. J Natl Compr Canc Netw 2007;5:99103.

  • 25.

    Association of Community Cancer Centers. 2014 Trends Survey. Accessed February 19, 2020. Available at: https://www.accc-cancer.org/home/learn/publications/Trends/2014

    • PubMed
    • Export Citation
  • 26.

    Donabedian A. Evaluating the quality of medical care. Milbank Mem Fund Q 1966;44:166206.

  • 27.

    Nipp RD, Powell E, Chabner B, et al.. Recognizing the financial burden of cancer patients in clinical trials. Oncologist 2015;20:572575.

  • 28.

    Aakhus E, Rosenstein A, Joffee S, Bradbury AR. Implementing cost transparency in oncology: a qualitative study of barriers, facilitators, and patient preferences [abstract]. J Clin Oncol 2017;35(Suppl):Abstract 6597.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 29.

    Bullock AJ, Hofstatter EW, Yushak ML, et al.. Understanding patients’ attitudes toward communication about the cost of cancer care. J Oncol Pract 2012;8:e5058.

  • 30.

    Shankaran V, Leahy T, Steelquist J, et al.. Pilot feasibility study of an oncology financial navigation program. J Oncol Pract 2018;14:e122129.

Metrics

All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 4591 1150 135
PDF Downloads 1618 320 35
EPUB Downloads 0 0 0